Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts Q3 results and reports positive Phase 2 MaGic trial data in gMG
Dianthus Therapeutics Inc. reported a net loss of $36.8 million, or $0.97 per share, for the quarter ended September 30, 2025, compared to a net loss of $25.2 million, or $0.74 per share, for the same period in 2024. The company estimates an adjusted cash, cash equivalents, and investments position of approximately $525.0 million as of September 30, 2025, after accounting for upfront and near-term milestone payments related to the licensing of DNTH212 from Nanjing Leads Biolabs. This cash position is projected to provide funding runway into 2028. Recent business developments include the closing of an upsized public offering raising about $288.0 million and the exclusive licensing agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569561-en) on November 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。